Analysts Offer Predictions for Cytokinetics Q1 Earnings

Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) - HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Cytokinetics in a note issued to investors on Friday, February 28th. HC Wainwright analyst J. Pantginis anticipates that the biopharmaceutical company will earn ($1.42) per share for the quarter. HC Wainwright has a "Buy" rating and a $120.00 price target on the stock. The consensus estimate for Cytokinetics' current full-year earnings is ($5.24) per share. HC Wainwright also issued estimates for Cytokinetics' Q2 2025 earnings at ($1.44) EPS, Q3 2025 earnings at ($1.44) EPS, Q4 2025 earnings at ($1.53) EPS and FY2025 earnings at ($5.83) EPS.

Cytokinetics (NASDAQ:CYTK - Get Free Report) last released its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($1.26) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.29) by $0.03. The firm had revenue of $16.93 million during the quarter, compared to analysts' expectations of $14.26 million.

CYTK has been the subject of a number of other research reports. Royal Bank of Canada boosted their price objective on shares of Cytokinetics from $80.00 to $82.00 and gave the company an "outperform" rating in a research report on Wednesday, December 18th. Mizuho upped their target price on Cytokinetics from $99.00 to $103.00 and gave the company an "outperform" rating in a report on Thursday, November 21st. Morgan Stanley raised Cytokinetics from an "equal weight" rating to an "overweight" rating and cut their price target for the stock from $70.00 to $67.00 in a report on Thursday, February 13th. Needham & Company LLC reaffirmed a "buy" rating and issued a $72.00 target price on shares of Cytokinetics in a research report on Thursday, February 6th. Finally, Evercore ISI raised shares of Cytokinetics to a "strong-buy" rating in a report on Friday, February 7th. Two analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $82.00.

Cytokinetics Stock Performance

Shares of CYTK stock traded down $0.25 on Monday, hitting $43.63. 313,576 shares of the stock traded hands, compared to its average volume of 1,570,474. The company has a market capitalization of $5.17 billion, a PE ratio of -8.10 and a beta of 0.95. Cytokinetics has a 1-year low of $40.53 and a 1-year high of $75.71. The company's fifty day moving average is $47.00 and its 200 day moving average is $51.03. The company has a debt-to-equity ratio of 5.93, a current ratio of 9.28 and a quick ratio of 9.28.

Insider Buying and Selling

In related news, EVP Fady Ibraham Malik sold 7,300 shares of the company's stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $50.64, for a total transaction of $369,672.00. Following the transaction, the executive vice president now directly owns 116,071 shares of the company's stock, valued at approximately $5,877,835.44. The trade was a 5.92 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Wendall Wierenga sold 742 shares of the firm's stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $48.61, for a total value of $36,068.62. Following the sale, the director now owns 24,559 shares of the company's stock, valued at $1,193,812.99. The trade was a 2.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 17,822 shares of company stock valued at $874,048 over the last three months. Company insiders own 3.40% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of CYTK. Van ECK Associates Corp raised its holdings in Cytokinetics by 21.3% in the 3rd quarter. Van ECK Associates Corp now owns 71,691 shares of the biopharmaceutical company's stock valued at $3,802,000 after acquiring an additional 12,565 shares in the last quarter. Harvey Capital Management Inc. acquired a new stake in shares of Cytokinetics in the 4th quarter valued at $1,040,000. Westfield Capital Management Co. LP increased its stake in shares of Cytokinetics by 38.9% in the third quarter. Westfield Capital Management Co. LP now owns 1,212,886 shares of the biopharmaceutical company's stock valued at $64,040,000 after buying an additional 339,373 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Cytokinetics by 42.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,321,391 shares of the biopharmaceutical company's stock valued at $69,769,000 after purchasing an additional 395,709 shares during the last quarter. Finally, abrdn plc increased its holdings in shares of Cytokinetics by 29.4% in the fourth quarter. abrdn plc now owns 450,513 shares of the biopharmaceutical company's stock valued at $21,192,000 after purchasing an additional 102,457 shares in the last quarter.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.